Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.
Google ScholarÂ
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–27.
Google ScholarÂ
Shah NJ, Ababio Y, Eccleston A, Rao D, Kelly SP, Chang J, et al. Axitinib-pembrolizumab and adverse event management in patients with advanced renal cell carcinoma. JAMA Netw Open. 2026;9:e2614061.
Google ScholarÂ
Huang K, Chen K. Immune escape in renal cell carcinoma: latest research and treatment strategies. Int J Mol Sci. 2026;27:3064.
Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76:e70043.
Google ScholarÂ
Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84.
Google ScholarÂ
Wang P, Zhang B, Shi Y, Wang Z, Wen S, Sethi G, et al. Tumor-specific mechanisms and therapeutic strategies for overcoming immunotherapy resistance in advanced urological tumors. J Adv Res 2026;S2090–1232:00580-1.
Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41:421–33.
Google ScholarÂ
Linehan WM, Ricketts CJ. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16:539–52.
Google ScholarÂ
Diaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16:721–35.
Google ScholarÂ
Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:709–24.
Google ScholarÂ
Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17:611–29.
Google ScholarÂ
Tripathi A, Lin E, Xie W, Flaifel A, Steinharter JA, Stern Gatof EN, et al. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer 2020;8:e001467.
Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer 2022;10:e004089.
Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, et al. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Nat Med. 2026;32:1267–77.
Google ScholarÂ
Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu Q, et al. Durvalumab alone or combined with novel agents for unresectable stage III non-small cell lung cancer: update from the coast randomized clinical trial. JAMA Netw Open. 2025;8:e2518440.
Google ScholarÂ
Cascone T, Bonanno L, Guisier F, Insa A, Liberman M, Bylicki O, et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. Nat Med. 2025;31:2788–96.
Google ScholarÂ
Coveler AL, Reilley MJ, Zalupski M, Macarulla T, Fountzilas C, Ponz-Sarvise M, et al. A phase Ib/II randomized clinical trial of oleclumab with or without durvalumab plus chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res. 2024;30:4609–17.
Google ScholarÂ
Fu Z, Chen S, Zhu Y, Zhang D, Xie P, Jiao Q, et al. Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity. Sci Adv. 2023;9:eadd6626.
Google ScholarÂ
Zhu Y, Banerjee A, Xie P, Ivanov AA, Uddin A, Jiao Q, et al. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers. J Clin Investig. 2024;134:e176390.
Chi JJ, Xie P, Cheng MH, Zhu Y, Cui X, Watson J, et al. MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer. Nat Commun. 2025;16:3552.
Google ScholarÂ
Archambault V, Carmena M. Polo-like kinase-activating kinases: Aurora A, Aurora B and what else? Cell Cycle. 2012;11:1490–5.
Google ScholarÂ
Borah NA, Reddy MM. Aurora Kinase B inhibition: a potential therapeutic strategy for cancer. Molecules 2021;26:1981.
Wong PY, Chan CYK, Xue HDG, Goh CC, Cheu JWS, Tse APW, et al. Cell cycle inhibitors activate the hypoxia-induced DDX41/STING pathway to mediate antitumor immune response in liver cancer. JCI Insight 2024;9:e170532.
Wang X, Huang J, Liu F, Yu Q, Wang R, Wang J, et al. Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression. J Clin Investig. 2023;133:e161929.
Jiang J, Wang J, Yue M, Cai X, Wang T, Wu C, et al. Direct Phosphorylation and stabilization of MYC by Aurora B kinase promote T-cell leukemogenesis. Cancer Cell. 2020;37:200–15.e205.
Google ScholarÂ
Tang T, Huang X, Lu M, Zhang G, Han X, Liang T. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and autocrine manner. Nat Commun. 2023;14:3364.
Google ScholarÂ
Han G, Spitzer MH, Bendall SC, Fantl WJ, Nolan GP. Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry. Nat Protoc. 2018;13:2121–48.
Google ScholarÂ
Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556–60.
Google ScholarÂ
Deshpande RP, Wu K, Wu SY, Tyagi A, Smith EC, Hunting J, et al. Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer. Mol Ther. 2024;32:3669–82.
Google ScholarÂ
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21.
Google ScholarÂ
Barata PC, Rini BI. Treatment of renal cell carcinoma: Current status and future directions. CA: A Cancer J Clin. 2017;67:507–24.
Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, et al. Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18:199–214.
Google ScholarÂ
Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021;6:72.
Google ScholarÂ
Goel S, DeCristo MJ, Watt AC, Brin-Jones H, Sceneay J, Li BB, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471–5.
Google ScholarÂ
Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91–5.
Google ScholarÂ
Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12:4536.
Google ScholarÂ
Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Gimenez-Capitan A, Cantero F, et al. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nat Commun. 2019;10:1812.
Google ScholarÂ
Zhu Q, Ding L, Zi Z, Gao S, Wang C, Wang Y, et al. Viral-mediated AURKB cleavage promotes cell segregation and tumorigenesis. Cell Rep. 2019;26:3657–71.e3655.
Google ScholarÂ
Hsu JM, Li CW, Lai YJ, Hung MC. Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res. 2018;78:6349–53.
Google ScholarÂ
Lee TA, Tsai EY, Liu SH, Hsu Hung SD, Chang SJ, Chao CH, et al. Post-translational modification of PD-1: potential targets for cancer immunotherapy. Cancer Res. 2024;84:800–7.
Google ScholarÂ
Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359–70.
Google ScholarÂ
Geffen Y, Anand S, Akiyama Y, Yaron TM, Song Y, Johnson JL, et al. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell. 2023;186:3945–67.e3926.
Google ScholarÂ
Zhang HL, Hu BX, Ye ZP, Li ZL, Liu S, Zhong WQ, et al. TRPML1 triggers ferroptosis defense and is a potential therapeutic target in AKT-hyperactivated cancer. Sci Transl Med. 2024;16:eadk0330.
Google ScholarÂ
Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287–305.
Google ScholarÂ
Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129:3324–38.
Google ScholarÂ
Apriamashvili G, Vredevoogd DW, Krijgsman O, Bleijerveld OB, Ligtenberg MA, de Bruijn B, et al. Ubiquitin ligase STUB1 destabilizes IFNgamma-receptor complex to suppress tumor IFNgamma signaling. Nat Commun. 2022;13:1923.
Google ScholarÂ
Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, et al. The UBA1-STUB1 axis mediates cancer immune escape and resistance to checkpoint blockade. Cancer Discov. 2025;15:363–81.
Google ScholarÂ
Zhang C, Zhang K, Gu J, Ge D. ENO1 promotes antitumor immunity by destabilizing PD-L1 in NSCLC. Cell Mol Immunol. 2021;18:2045–7.
Google ScholarÂ
